Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Human Factors

Date Submitted: Oct 2, 2024
Date Accepted: Dec 31, 2024

The final, peer-reviewed published version of this preprint can be found here:

An AI-Based Clinical Decision Support System for Antibiotic Therapy in Sepsis (KINBIOTICS): Use Case Analysis

Düvel JA, Lampe D, Kirchner M, Elkenkamp S, Cimiano P, Düsing C, Marchi H, Schmiegel S, Fuchs C, Claßen S, Meier KL, Borgstedt R, Rehberg S, Greiner W

An AI-Based Clinical Decision Support System for Antibiotic Therapy in Sepsis (KINBIOTICS): Use Case Analysis

JMIR Hum Factors 2025;12:e66699

DOI: 10.2196/66699

PMID: 40036494

PMCID: 11896086

KINBIOTICS – Use case analysis of an AI-based clinical decision support system for antibiotic therapy in sepsis

  • Juliane Andrea Düvel; 
  • David Lampe; 
  • Maren Kirchner; 
  • Svenja Elkenkamp; 
  • Philipp Cimiano; 
  • Christoph Düsing; 
  • Hannah Marchi; 
  • Sophie Schmiegel; 
  • Christiane Fuchs; 
  • Simon Claßen; 
  • Kirsten-Laura Meier; 
  • Rainer Borgstedt; 
  • Sebastian Rehberg; 
  • Wolfgang Greiner

ABSTRACT

Background:

Antimicrobial resistances pose significant challenges in healthcare systems. Clinical decision support systems (CDSS) represent a potential strategy for promoting a more targeted and guideline-based use of antibiotics. The integration of artificial intelligence (AI) into these systems has the potential to support physicians in selecting the most effective drug therapy.

Objective:

This study aims to analyze the feasibility of an AI-based CDSS pilot version for antibiotic therapy in sepsis patients and identify facilitating and inhibiting conditions for its implementation in intensive care medicine.

Methods:

The evaluation was conducted in two steps, employing a qualitative methodology. Initially, expert interviews were conducted, in which intensive care physicians were asked to assess the AI-based recommendations for antibiotic therapy in terms of plausibility, layout and design. Subsequently, focus group interviews were conducted to examine the technology acceptance of the AI-based CDSS. The interviews were anonymized and evaluated using content analysis.

Results:

With regard to the feasibility of the intervention: The majority of physicians have a positive attitude towards AI-based CDSS. The assessment of AI-based recommendations largely depends on plausibility and professional experience. A central element for the acceptance of the AI-based CDSS was the time factor. A lack of digitization in the clinics was identified as a major inhibiting factor. According to the physicians, the heterogeneous use of antibiotics in practice to date also has a negative impact on the predictive ability of the AI-based CDSS.

Conclusions:

Early integration of users is beneficial for both the identification of relevant context factors and the further development of an effective CDSS. Overall, the potential of AI-based CDSS is offset by inhibiting contextual conditions that impede its acceptance and implementation. The advancement of AI-based CDSS and the mitigation of these inhibiting conditions are crucial for the realization of its full potential.


 Citation

Please cite as:

Düvel JA, Lampe D, Kirchner M, Elkenkamp S, Cimiano P, Düsing C, Marchi H, Schmiegel S, Fuchs C, Claßen S, Meier KL, Borgstedt R, Rehberg S, Greiner W

An AI-Based Clinical Decision Support System for Antibiotic Therapy in Sepsis (KINBIOTICS): Use Case Analysis

JMIR Hum Factors 2025;12:e66699

DOI: 10.2196/66699

PMID: 40036494

PMCID: 11896086

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.